Search
01/08/2023
Quantifying the benefit of nonselective beta-blockers in the prevention of hepatic decompensation: A Bayesian reanalysis of the PREDESCI trial
Rowe, IA, Villanueva, C, Shearer, JE, Torres, F, Albillos, A, Genesca, J, Garcia-Pagan, JC, Tripathi, D, Hayes, PC, Bosch, J, Abraldes, JG. Quantifying the benefit of nonselective beta-blockers in the prevention of hepatic decompensation: A Bayesian reanalysis of the PREDESCI trial. HEPATOLOGY. 2023; 78(2)DOI:10.1097/HEP.0000000000000342. PMID:36897269. IF:13.000(Q1/1D).
01/08/2023
Outcomes of octogenarians and nonactogenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective study
Atamna, A, Margalit, I, Ayada, G, Babich, T, Naucler, P, Valik, JK, Giske, CG, Benito, N, Cardona, R, Rivera, A, Pulcini, C, Fattah, MA, Haquin, J, Macgowan, A, Chazan, B, Yanovskay, A, Ben Ami, R, Landes, M, Nesher, L, Zaidman-Shimshovitz, A, McCarthy, K, Paterson, DL, Tacconelli, E, Buhl, M, Mauer, S, Rodriguez-Bano, J, de Cueto, M, Oliver, A, de Gopegui, ER, Cano, A, Machuca, I, Gozalo-Marguello, M, Martinez-Martinez, L, Gonzalez-Barbera, EM, Alfaro, IG, Salavert, M, Beovic, B, Saje, A, Mueller-Premru, M, Pagani, L, Vitrat, V, Kofteridis, D, Zacharioudaki, M, Maraki, S, Weissman, Y, Paul, M, Dickstei, Y, Yahav, D. Outcomes of octogenarians and nonactogenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective study. INFECTION. 2023; 51(4)DOI:10.1007/s15010-022-01973-x. PMID:36571672. IF:5.400(Q1/2D).
01/08/2023
PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
Isla, D, Sanchez, A, Casal, J, Cobo, M, Majem, M, Reguart, N, Zugazagoitia, J, Bernabe, R. PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. Journal of Clinical Medicine. 2023; 12(15)DOI:10.3390/jcm12155063. PMID:37568465. IF:3.000(Q1/2D).
01/08/2023
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
Grunwald, V, Powles, T, Kopyltsov, E, Kozlov, V, Alonso-Gordoa, T, Eto, M, Hutson, T, Motzer, R, Winquist, E, Maroto, P, Keam, B, Procopio, G, Wong, SR, Melichar, B, Rolland, F, Oya, M, Rodriguez-Lopez, K, Saito, K, McKenzie, J, Porta, C. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. European Urology Oncology. 2023; 6(4)DOI:10.1016/j.euo.2023.01.010. PMID:36720658. IF:8.300(Q1/1D).